Antibodies of programmed death-1 (PD-1) and its ligand (PD-L1), for example, are utilized for the therapy of NSCLC to stimulate anti-tumour immune responses by preventing inhibitory immunological signals. This evidence concerns the gene CD274 and non-small cell lung carcinoma.